andecaliximab

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent Wednesday morning after the company's first quarter earnings and revenue fell short of what analysts were expecting. Although Gilead's numbers point to a top-and-bottom line beat, Barclays' Geoff...